Our findings indicate that therapeutic inhibition of cholesterol biosynthesis may be a viable approach to suppress breast cancer metastasis, possibly with greater benefit for patients with low-BMP4-expressing tumours as exemplified by the 231-HM tumour line. This evidence concerns the gene BMP4 and breast carcinoma.